PTGX logo

PTGX
Protagonist Therapeutics Inc

3,357
Mkt Cap
$6.51B
Volume
2,214.00
52W High
$107.84
52W Low
$39.90
PE Ratio
-49.98
PTGX Fundamentals
Price
$102.09
Prev Close
$103.75
Open
$104.28
50D MA
$91.79
Beta
0.54
Avg. Volume
967,587.33
EPS (Annual)
-$2.05
P/B
10.39
Rev/Employee
$348,606.06
$4,995.43
Loading...
Loading...
News
all
press releases
SG Americas Securities LLC Sells 21,249 Shares of Protagonist Therapeutics, Inc. $PTGX
SG Americas Securities LLC reduced its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 51.5% in the 4th quarter, according to the company in its most recent filing with the...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High - What's Next?
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High - What's Next...
MarketBeat·8d ago
News Placeholder
Arturo Md Molina Sells 15,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) insider Arturo Md Molina sold 15,000 shares of the stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $104.79, for a total transaction of $1,571,850.00. Following the sale, the insider owned...
MarketBeat·12d ago
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells $2,581,503.60 in Stock
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CFO Asif Ali sold 24,765 shares of Protagonist Therapeutics stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $104.24, for a total transaction of $2,581,503.60. Following the completion of...
MarketBeat·12d ago
News Placeholder
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 24,000 Shares of Stock
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) Director Harold Selick sold 24,000 shares of the firm's stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $105.00, for a total transaction of $2,520,000.00. Following the...
MarketBeat·12d ago
News Placeholder
Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE?
JNJ's Innovative Medicine unit eyes Q1 growth on key drug momentum, but biosimilar pressure and Stelara's decline may weigh on results.
Zacks·13d ago
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's What Happened
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Still a Buy...
MarketBeat·14d ago
News Placeholder
J&J's Pipeline Surge Sets Up Stronger Growth From New Drugs in 2026
JNJ's rapid pipeline progress and new drug approvals in 2025 set the stage for stronger growth impact from its expanding portfolio in 2026.
Zacks·14d ago
News Placeholder
JPMorgan Chase & Co. Decreases Stake in Protagonist Therapeutics, Inc. $PTGX
JPMorgan Chase & Co. lessened its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 42.6% in the 3rd quarter, according to its most recent filing with the Securities...
MarketBeat·14d ago
News Placeholder
Dinesh Ph Patel Sells 54,641 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CEO Dinesh Ph Patel sold 54,641 shares of the business's stock in a transaction dated Wednesday, March 25th. The stock was sold at an...
MarketBeat·15d ago
<
1
2
...
>

Latest PTGX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.